What Lorista treats: main uses and benefits

Lorista (losartan) is an antihypertensive medication belonging to the class of angiotensin II receptor blockers (ARBs). It is primarily used to manage cardiovascular conditions by helping to relax blood vessels, which lowers blood pressure and improves blood flow.

Essential Hypertension

The primary application of Lorista is the treatment of essential hypertension (high blood pressure) in adults, as well as in children and adolescents aged 6 to 18 years. By reducing systemic vascular resistance, the medication helps maintain blood pressure within a target range, which reduces the long-term strain on the heart and arteries.

Renal Protection in Type 2 Diabetes

Lorista is indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus. It is used as part of a therapeutic strategy to provide nephroprotection, specifically for patients with proteinuria (the presence of protein in the urine). In these cases, the medication helps slow the progression of kidney damage and reduces the risk of reaching end-stage renal disease.

Reduction in Risk of Stroke

In patients with hypertension and left ventricular hypertrophy (a thickening of the walls of the heart's main pumping chamber), Lorista is used to reduce the risk of cardiovascular morbidity and mortality, specifically focusing on the reduction of stroke incidence.

Chronic Heart Failure

Lorista may be utilized in the treatment of chronic heart failure in adult patients when treatment with specific other heart medications, such as ACE inhibitors, is considered unsuitable due to incompatibility or specific contraindications. It aims to improve cardiac efficiency and reduce the frequency of hospitalizations related to heart failure symptoms.

Regulatory References

1. The National Library of Medicine (DailyMed) provides detailed information on its uses.

Eligibility Scope for Losartan Potassium

Population Status	Restriction Criteria
Contraindicated	Pregnancy (2nd and 3rd trimesters), due to risk of fetal injury and death.
Contraindicated	Hypersensitivity to losartan or any excipients, and in severe hepatic impairment.
Contraindicated	Concomitant use with aliskiren in patients with diabetes or moderate-to-severe renal impairment.

Age-Group Eligibility Rules: The medicine is officially established for use in adults across all approved indications. In the pediatric population, eligibility is limited to the treatment of hypertension in children aged 6 years and older. Use is not recommended in children under 6 years of age, as safety and efficacy have not been established in this age group.

Condition-Specific Eligibility: A lower initial dose is considered for patients with mild-to-moderate hepatic impairment due to the potential for increased drug concentration. Patients with pre-existing conditions like intravascular volume depletion (e.g., from high-dose diuretics) must have the condition corrected or start at a lower dose. Use requires special caution in patients with renal artery stenosis. Losartan is not recommended for use during the first trimester of pregnancy or by lactating/nursing mothers.

Interactions with other medicines and products

Losartan's interaction profile is based on pharmacodynamic effects and metabolic pathways, as documented in regulatory information.

Contraindicated Combinations

The simultaneous use of Losartan (an ARB) with aliskiren is contraindicated in patients diagnosed with Diabetes Mellitus or renal impairment (specifically, those with an estimated GFR less than 60 mL/min/1.73 m²). This restriction addresses the increased risk associated with dual Renin-Angiotensin-Aldosterone System (RAAS) blockade.

Clinically Significant Pharmacodynamic Interactions

Substance Type	Interaction Outcome	Constraint
Potassium-Sparing Diuretics/Supplements	Increased risk of hyperkalemia	Not generally recommended
NSAIDs (including COX-2 Inhibitors)	Reduced antihypertensive effect; increased risk of worsening renal function	Requires caution and monitoring
Lithium	Increased serum lithium concentrations and toxicity	Requires monitoring of lithium levels

Pharmacokinetic Considerations

Losartan is metabolized to its active metabolite by CYP2C9 and CYP3A4 enzymes. Drugs that inhibit these enzymes, such as fluconazole (a strong CYP2C9 inhibitor), can reduce the formation of the active metabolite, while enzyme inducers (e.g., phenobarbital) can decrease the plasma concentrations of Losartan and its active form. Food intake does not significantly affect the overall extent of Losartan absorption.

Лориста, which contains the active substance losartan, functions as a selective and competitive antagonist of the Angiotensin II type 1 (AT1) receptor. Following oral administration, losartan undergoes first-pass hepatic metabolism via Cytochrome P450 isoenzymes (primarily CYP2C9 and CYP3A4) to form the principal active metabolite, EXP 3174.

Both losartan and EXP 3174 bind to AT1 receptors located on vascular smooth muscle cells, the adrenal glands, the heart, and the kidneys. This molecular interaction competitively prevents the binding of the endogenous agonist Angiotensin II, effectively blocking the downstream signaling cascade mediated by AT1 receptor activation.

Intracellularly, this blockade inhibits the Gq-protein signaling pathway, leading to decreased activation of phospholipase C and subsequent reduction in intracellular calcium release. At a systemic level, the prevention of Angiotensin II binding to AT1 receptors modulates several physiological responses: it inhibits vasoconstriction, decreases the release of aldosterone from the adrenal cortex, and suppresses the Angiotensin II-mediated sympathetic nervous system activation.

The overall physiological consequence of AT1 receptor antagonism is a reduction in total peripheral resistance and a modulation of fluid and electrolyte homeostasis through decreased sodium and water reabsorption.

How to Use Лориста: Official Administration Guidelines

Losartan Potassium (Лориста) is administered strictly via the oral route, typically using film-coated tablets in strengths of 25 mg, 50 mg, or 100 mg. The primary dosing schedule requires administration once daily (q.d.) for all approved indications. The tablets may be taken with or without food and should be swallowed whole. If a dose is missed, it is instructed to take the next dose at the usual time and not to double the dose to compensate.

---

Standard Dosing and Titration

Therapy is generally initiated at 50 mg once daily for most adult patients. The dosage can be adjusted based on response, but must not exceed the maximum amount of 100 mg once daily. Importantly, any dose titration to a higher level is not immediate, as the full therapeutic effect typically requires 3 to 6 weeks of consistent use at the current dosage.

---

Population-Specific Use

Specific physiological conditions require an adjusted initial dose to follow official guidelines:

Patient Population	Initial Dose
Hepatic Impairment (Mild-to-Moderate)	Lower dose of 25 mg once daily
Volume Depletion (e.g., on high-dose diuretics)	Lower dose of 25 mg once daily
Pediatric Patients (6–16 years)	Weight-based, starting at 0.7 mg/kg once daily (Max 50 mg)

Losartan is intended for long-term treatment of chronic conditions, and the labeled instructions define this standardized oral, once-daily protocol, with clear adjustments required before initiation in specific groups.

Research Evidence / Overview of Studies for Лориста

Evidence for Use in Managing Essential High Blood Pressure

Research exploring Losartan for essential high blood pressure was conducted through large-scale Randomized Controlled Trials (RCTs) and subsequent extensive systematic reviews. These studies primarily examined adult populations and focused on changes in both the upper (Systolic) and lower (Diastolic) blood pressure measurements. Some trials described patterns related to blood pressure changes when the product was used over intermediate to long periods. The research provides insight into short-term changes in blood pressure and how blood pressure patterns were observed in some studies to be maintained over several years.

Evidence for Use in Protecting Kidneys in Type 2 Diabetes

The evidence base for Losartan in patients with Type 2 Diabetes and signs of kidney disease (diabetic nephropathy) is extensive, primarily centered on dedicated, long-term, randomized outcome trials. Researchers focused on composite endpoints related to the progression of kidney disease, such as the need for dialysis. Studies reported measurements of composite endpoint rates related to the progression of renal disease, which were observed to be different when compared to placebo. Findings also indicate that Losartan was observed in some studies where changes in proteinuria (protein in the urine) were monitored.

Evidence for Use in Reducing Risk for Hypertensive Patients with LVH

Research exploring Losartan’s role in hypertensive patients who also have Left Ventricular Hypertrophy (LVH) involved large-scale, long-term comparative outcome trials. These studies primarily examined the incidence of specific cardiovascular events, notably stroke, when Losartan was compared to another commonly used antihypertensive drug. The main comparative trial described patterns related to the rate of first-ever stroke compared to the specific drug used in the study.

What Research Gaps and Uncertainties Remain

Data for certain groups remain insufficient. For instance, long-term effects in the pediatric population (under 18) are not fully established due to follow-up durations that were shorter in this subgroup. Comparative evidence is lacking against the newest or alternative medications within the same class or other classes of antihypertensives. Findings were mixed in certain racial or ethnic subgroups in the LVH trials, indicating that results apply only to the populations studied and that subgroup findings are uncertain.

Common questions about Лориста (FAQ)

Q: Can Losartan cause weight gain or loss?

Official product labeling for losartan does not commonly list weight gain or weight loss as a frequent side effect. However, some regulatory documents note reports of edema, which is fluid retention. Any significant fluid retention has the potential to cause weight changes, which can be discussed with a healthcare provider.

---

Q: How does Losartan affect the liver?

Losartan is processed by the liver, and official information indicates that the medicine is contraindicated (not recommended) in patients with severe liver impairment. While rare, post-marketing surveillance reports have documented cases of acute liver injury, such as hepatitis (liver inflammation). Questions regarding liver health can be addressed by a healthcare provider.

---

Q: Can I drink alcohol while taking Losartan?

According to official regulatory sources, consuming alcohol can increase the blood pressure-lowering effect of Losartan. This effect may increase the risk of experiencing dizziness or light-headedness. Patients should always discuss the use of alcohol with their healthcare provider.

---

Q: Is Losartan addictive?

No, Losartan is not classified as a controlled substance by regulatory bodies, and it is not considered to be an addictive medication. It is an Angiotensin II Receptor Blocker (ARB) prescribed for the long-term management of chronic conditions.

---

Q: How should I dispose of expired or unused Losartan tablets?

Regulatory guidance suggests that unused or expired Losartan should not be flushed down the toilet. Safe disposal includes using an authorized drug take-back program if one is available. If a program is not available, the medicine may be mixed with an undesirable substance, such as used coffee grounds, sealed in a container, and placed into the household trash.

How to Store and Dispose of Лориста?

This section outlines the official, label-based requirements for storing and discarding the Losartan Potassium oral tablets.

Storage Requirement	Official Condition (Regulatory Basis)
Temperature	Store at Controlled Room Temperature (20 C to 25 C), with permitted excursions between 15 C and 30 C.
Protection	Keep the medicine away from excess heat, light, and moisture; storage in bathrooms is prohibited.
Container Rule	Keep the tablets in the container they came in, and ensure the container is tightly closed.
Child Safety	The medication must be secured out of the sight and reach of children using locked safety caps or secure, high-up placement.

Disposal Requirements

To discard unused or expired Losartan, follow authorized programs such as a drug take-back location. If a take-back program is unavailable, the medicine should be mixed with an undesirable substance (e.g., used coffee grounds), sealed in a bag or container, and disposed of in household trash. It is explicitly required not to use the medicine past its expiry date, and disposal must always align with local authority regulations.